More broadly, any condition of impaired copper excretion or unusual copper sensitivity is a conceptual red flag for a systemically administered copper peptide
Varela JG, Pierce LE, Guo X, Price NE, Johnson KM, Yang Z, et al
MMPs, particularly MMP-9, and proteins such as HMGB1 have also been implicated in BBB breakdown, highlighting the need for further research into these pathways as potential therapeutic targets for AD [184,203,204]
Clinical experience suggests good tolerability, with: Mild injection site reactions Occasional digestive changes (particularly with oral administration) Rarely reported headache Important Safety Considerations Both peptides should be prescribed and monitored by qualified medical providers Quality of peptide sourcing matters compounding pharmacies should be licensed and regulated Lab monitoring (particularly IGF-1 for sermorelin) is essential for ongoing safety Contraindications (active malignancies, certain medical conditions) must be evaluated Medical Disclaimer Sermorelin was previously FDA-approved for diagnostic use (Geref Diagnostic) and is currently prescribed off-label through compounding pharmacies
New blood vessels develop during healing
